Omnicell stock holds near USD 30 as Q2 growth reaches 15 percent

Omnicell stock traded at about USD 30.00 on Nasdaq on September 21, 2026, while the company reported second-quarter revenue of about USD 310 million and adjusted EPS of about USD 0.40 for Q2 2026. The share price remains below earlier highs above USD 50.00, making the latest operating growth more important for valuation than a short-term price move.

Q2 revenue rises 15 percent

According to Ad-hoc News on September 21, 2026, Omnicell generated about USD 310 million in Q2 2026 revenue, compared with about USD 270 million in the prior-year quarter. That represents growth of about 15 percent, while adjusted EPS reached about USD 0.40 in Q2 2026.

The comparison gives the stock a measurable operating reference: revenue increased by about USD 40 million year over year, while adjusted earnings stayed within the expectations previously communicated by the company. The revenue advance is therefore the clearest reported growth figure available for the current valuation discussion.

2026 guidance sets the frame

Omnicell is targeting fiscal-year 2026 revenue growth in the mid-single-digit to low-double-digit percentage range, according to the September 21, 2026 report from Ad-hoc News. The guidance links the outlook to continued automation demand from hospitals and pharmacies.

For investors, the key tension is visible in the numbers. Q2 revenue growth of about 15 percent was above the mid-single-digit starting point of the annual growth range, but the share price near USD 30.00 remained well below historical levels above USD 50.00 as of September 21, 2026. That gap leaves execution against the full-year range as the central operating checkpoint.

Stock remains below earlier highs

Omnicell stock was quoted at about USD 30.00 on Nasdaq on September 21, 2026. The same dated market context places the company in the single-digit billions of US dollars by market capitalization and shows the stock well below earlier highs above USD 50.00.

The market data and Q2 figures point in different directions: operating revenue rose from about USD 270 million to USD 310 million year over year, while the share price stayed roughly USD 20 below the earlier high level. The next valuation signal will come from whether reported growth continues to support the fiscal-year 2026 revenue range.

More news and analyses on Omnicell stock